logo
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Business Wire14-05-2025

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan on June 14, 2025. Anito-cel is partnered with Kite, a Gilead Company.
The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a minimum follow-up of four months after treatment with anito-cel. All patients received a single infusion of anito-cel (target dose of 115×10 6 CAR+ viable T cells). 101 of 117 patients (86%) were triple refractory, and 48 of 117 patients (41%) were penta refractory. Patients received a median of three prior lines of therapy, with 60 of 117 patients (51%) having received three prior lines.
Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at the time of this data cut, 93.3% (70/75) achieved MRD negativity at a minimum of 10 -5 sensitivity. Six-month progression-free survival (PFS) and overall survival (OS) rates were 91.9% and 96.6%, respectively, and 12-month PFS and OS rates were 78.8% and 95.2%, respectively. Median PFS and median OS have not been reached.
No delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel. No additional treatment- or therapy-related deaths or Grade ≥3 cytokine release syndrome (CRS) or ICANS events have occurred since the previous data presentation in December 2024.
Conclusions
Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population, including triple- and penta-class refractory disease. Notably, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed with anito-cel to date.
'These clinical data from our registrational study continue to support our belief that anito-cel has the potential to address the needs of myeloma patients and the physicians who serve them,' said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. 'There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible. Anito-cel has the unique potential to address these needs thanks to our differentiated technology, our incredible and entrepreneurial team, the robust clinical data generated to date, and our strong partnership with Kite. Our 2026 commercial launch plans for anito-cel with our partners at Kite are well underway and we are excited for the opportunity to advance anito-cel in support of the myeloma community. We look forward to sharing these data with the clinical community at EHA and are honored that the iMMagine-1 data will be presented during an oral presentation on Saturday, June 14.'
EHA2025 Presentation Details
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial
Speaker: Gurbakhash Kaur, M.D., Assistant Professor of Internal Medicine, Mount Sinai Health System
Session Title: s431 Treatment of relapsed and/or refractory multiple myeloma (RRMM)
Session Date: June 14, 2025
Session Time: 17:00-18:15 CEST
Publication Number: S201
Presentation Title: S201 Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1
About Multiple Myeloma
Multiple Myeloma (MM) is a type of hematological cancer in which diseased plasma cells proliferate and accumulate in the bone marrow, crowding out healthy blood cells and causing bone lesions, loss of bone density, and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment, called a myeloma protein (M protein), causing kidney damage and impairing the patient's immune function. MM is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all hematological cancer cases and 20% of deaths due to hematological malignancies. The median age of patients at diagnosis is 69 years with one-third of patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple co-morbidities and toxicities that can quickly escalate and become life-endangering.
About Anitocabtagene Autoleucel (anito-cel)
Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes Arcellx's novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration.
About Arcellx and Kite Collaboration
Arcellx and Kite, a Gilead Company, formed a global strategic collaboration and license agreement to co-develop and co-commercialize anito-cel for patients with multiple myeloma. Anito-cel is currently being developed in a Phase 2 registrational pivotal study and a global Phase 3 randomized controlled study for relapsed and/or refractory multiple myeloma (RRMM). Kite and Arcellx will jointly commercialize the anito-cel asset in the United States, and Kite will commercialize the product outside the United States.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X @arcellx and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding the safety and efficacy of anito-cel, the promising clinical profile of anito-cel, the expectation of anito-cel to be a differentiated CAR-T treatment option for RRMM, the potential of anito-cel as an outpatient therapy, and the planned commercial development of anito-cel both inside and outside the United States. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and the other documents that Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Newmark Title Services Provides Title, Escrow Services for $700 Million, National Multifamily Portfolio Recapitalization
Newmark Title Services Provides Title, Escrow Services for $700 Million, National Multifamily Portfolio Recapitalization

Yahoo

time23 minutes ago

  • Yahoo

Newmark Title Services Provides Title, Escrow Services for $700 Million, National Multifamily Portfolio Recapitalization

NEW YORK, June 12, 2025 /PRNewswire/ -- Newmark Title Services announces that the Company provided title and escrow services for the $700 million recapitalization and refinancing of a national multifamily portfolio owned by Nitya Capital. The 18-property, six-state portfolio includes a blend of Class A student housing and Class B market-rate multifamily assets in high-growth markets such as Dallas, Indianapolis, the Carolinas, Nashville, Phoenix and Las Vegas. The transaction was executed through a Single Asset Single Borrower (SASB) loan structure and required the coordination of a top-tier bank, multiple advisory firms and legal counsel. Newmark Title Services played a central role in managing the closing process from start to finish, overseeing a highly complex set of deal components across a large and diverse asset base. "This transaction demonstrates the depth of expertise and coordination our team brings to large, sophisticated capital events," said Marc Israel, President of Newmark Title Services. "With over a dozen of our professionals dedicated to this assignment, we delivered seamless execution and timely closing for one of the year's most complex multifamily financings." The closing process extended over several months. Newmark Title Services' ability to unify all aspects of title and escrow across the portfolio helped ensure the successful execution of the transaction. "This transaction highlights how Newmark's integrated service offerings can help clients achieve an optimal outcome in even the most complex financings," said Chad Lavender, President of Capital Markets for North America at Newmark. "By delivering precision and efficiency through Newmark Title, we help unlock value and drive results for clients across the commercial real estate landscape." Now operating as Newmark Title Services, our team of professionals leverages a strong foundation built through the 2018 acquisition of the New York City-based, national title agency MiT National Land Services. This strategic integration brought MiT's superior title industry practice into Newmark's expanding suite of commercial real estate services. Since then, Newmark Title Services has grown its national footprint, efficiently facilitating the closing of commercial real estate transactions across the country. About NewmarkNewmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries ("Newmark"), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark's comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform's global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended March 31, 2025, Newmark generated revenues of over $2.8 billion. As of March 31, 2025, Newmark and its business partners together operated from 165 offices with approximately 8,100 professionals across four continents. To learn more, visit or follow @newmark. Discussion of Forward-Looking Statements about NewmarkStatements in this document regarding Newmark that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K. View original content to download multimedia: SOURCE Newmark Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Spotify's new HR leader masterminded her company's remote work policy and gives one piece of key advice
Spotify's new HR leader masterminded her company's remote work policy and gives one piece of key advice

Yahoo

time27 minutes ago

  • Yahoo

Spotify's new HR leader masterminded her company's remote work policy and gives one piece of key advice

Spotify has found a new HR leader: Anna Lundström. The native Swede was appointed as CHRO of the music streaming giant in April of this year. She previously served as VP of HR, and has been with the company since 2016. One of Lundström's most notable contributions to the company so far was the formation of the company's 'work from anywhere' policy, which launched in 2021. A Spotify spokesperson previously told Fortune that the remote work strategy led to a 50% drop in attrition. In her new role, Lundström oversees all aspects of the company's human resources department, including people strategy, and managing a workforce of 7,500 employees across 180 markets. And her appointment comes at an exciting time for Spotify: the company celebrated its first full year of profitability since it was founded in 2008. Lundström sat down with Fortune to discuss her vision for the CHRO role, plans to integrate AI into her department's workflow, focusing on employee mental health, and connecting people strategy with business strategy. This interview has been edited and condensed for clarity. Fortune: What first brought you to Spotify? Anna Lundström: I was with NASDAQ for almost a decade before joining Spotify. I still had about 20 years in HR, but was obviously working in more of a financial services environment. I loved it, but Spotify reached out and was just starting to expand in the U.S. [Spotify] is obviously a product that I love and use, so that was important for me as I took my next step, but also the match with me being a Swede in the U.S. and being part of the Spotify journey and expansion here, was really attractive. You've said that one of the goals is to make AI a key focus across the organization. How are you planning to integrate AI into your HR department? My team partners closely with the product and technology team. A couple weeks ago, Gustav [Söderström], our chief product officer, and I, went out to the full organization with a set of guiding principles around not only the importance of AI, but [how] we are taking the learning approach. A lot of companies are missing out [by] saying, 'Get on the AI train!' But they're not really doing that. They just want to be fast and out there with the world. We launched a set of trainings for our employees—everything from prompt trainings to more advanced ones, based on your role. It's not about rolling out [AI]. It's rolled out, and now everyone is working on learning. Leaning fully into the learning, making our employees future ready, providing them with AI literacy skills—that will position them really well. We don't know what the future will hold, but the bet we're taking is making everyone AI ready. In HR specifically, we have also been early adopters. We've had a couple of people analytics tools for about two years. Disco is one of them, which gives us real time data. So no more Excel spreadsheets. We go into a Disco feature we've built ourselves that gets real time attrition, engagement, and more. We have another platform, Echo, that is built on machine learning and serves as our internal LinkedIn. What are some of your other priorities as CHRO? Another big focus is mental health. We're really leaning into that. We have doubled down on more support for our employees. This year we launched a new mental health platform that provides a more personalized experience, Modern Health. We believe that a sustainable and healthy workforce is a competitive advantage. Retaining our top talent is a massive focus of mine. Culture is always evolving. Product and business have evolved a lot one year into profitability. For me, a genuine people experience is when you really tie people strategy to business strategy, and they are one. One of Spotify's hallmarks is its 'Work from Anywhere' policy. How do you view the RTO debate in 2025? Fun fact: My colleague, Alexander Westerdahl, and I were the architects of that policy. We launched early in 2021. One of our key success factors, as a product but also in our employee offerings, is that we do not look at other companies that much. Of course we set benchmarks. But we have always believed that we have really talented, driven employees with high agency—motivation to work hard, have fun and deliver on the results. Then we don't necessarily care where you work from. What we have found in the years since we started 'Work from Anywhere' is that we need to have those touch points where people come together. We recently implemented what we call 'Core Week,' which is one week per year when your core team comes together and you work from an office of your choosing. The whole purpose is coming together, working, socializing, and planning together. What mistakes do you think leaders are making when it comes to RTO? When we launched Work from Anywhere, we said that [companies] need to do what's right for their business. It's not a one-size-fits-all. If you really trust and respect your employees, as long as you're able to explain the reasoning, then you can pick whatever works for you. Which Spotify benefits are you most proud of? Parental leave is huge. Our employees love it. Six months, all paid. For all parents: men, women, same sex couples, those carrying a child via surrogacy—it's for everyone. One of our most beloved ones is what we call Wellness Week. That came out of the pandemic. Everyone was at home and getting Zoom fatigue. So we came up with an idea to offer one week where the whole company is off. So now we are, for the fifth year in a row, closing all our offices in the first week of November. All 7,500 people, including executive management—no emails, no slacks, no WhatsApp. People go and spend their time recharging, being with their families. People love that because usually, when you're on vacation, you come back to a full inbox and a long to-do list. But here, everyone's off at the same time. Sometimes CHROs can be left out of conversations around the C-suite. What is your relationship like to the other executive leaders at Spotify? One of the key success factors of being an effective HR professional, at all levels, is obviously your capability to build relationships, to harness the relationships, act with high integrity. But it's also about being able to connect the dots between business, product priorities and people strategy—that's high level. I've been with the company for 10 years. I've supported almost all teams in the organization. I know the business and product inside and out. I've spent a lot of time with our C-suite and executive team. Once a week, the 'E-team,' or executive team, meets for three hours every Tuesday afternoon. We discuss top priorities, how we're tracking progress on these priorities, people and culture items, whatever that may be. That has made us so connected and collaborative and fast as an organization. I feel extremely well positioned for the job based on my tenure here and where I've worked in the organization and the relationships I've had. This story was originally featured on

Triple-I: US Personal Auto Insurance Industry Generates Profitable Underwriting Result but Faces Headwinds Due to Legal System Abuse, Regulatory Environment
Triple-I: US Personal Auto Insurance Industry Generates Profitable Underwriting Result but Faces Headwinds Due to Legal System Abuse, Regulatory Environment

Business Wire

time32 minutes ago

  • Business Wire

Triple-I: US Personal Auto Insurance Industry Generates Profitable Underwriting Result but Faces Headwinds Due to Legal System Abuse, Regulatory Environment

MALVERN, Pa.--(BUSINESS WIRE)--The United States personal auto insurance industry achieved its strongest underwriting performance in the post-pandemic era, recording a net combined ratio of 95.3 in 2024, but continues to face headwinds due to escalating legal system abuse and a challenging regulatory environment, according to a new Issues Brief published today by the Insurance Information Institute (Triple-I). "The growing impacts of legal system abuse, driven by the exploitive tactics of billboard attorneys, combined with an increasingly complex regulatory environment, will continue to put pressure on the market." 'While the improved 2024 underwriting performance is encouraging, we remain focused on several challenges facing the personal auto insurance industry,' said Triple-I CEO Sean Kevelighan. 'The growing impacts of legal system abuse, driven by the exploitive tactics of billboard attorneys, combined with an increasingly complex regulatory environment, will continue to put pressure on the market. It's essential for auto insurers to continue managing these evolving risks effectively to sustain profitable growth.' Key Performance Highlights Triple-I's Issues Brief showed the personal auto insurance sector's improvement across multiple metrics in 2024: Premium Growth: The industry maintained robust growth momentum with a net written premium increase of 12.8% in 2024, following 14.4% growth in 2023. This marks two consecutive years of double-digit premium growth, outpacing the broader U.S. property/casualty (P/C) industry for the second consecutive year. Loss Performance: Direct incurred loss ratios improved dramatically, falling 21.7 percentage points from a peak of 86% in Q4 2022 to 64% by the end of 2024. This substantial improvement reflects the industry's successful efforts to align pricing with risk and implement effective loss control measures. Historical Context: The personal auto line has outperformed the net combined ratio of the overall U.S. P/C industry in 10 of the past 20 years since 2005. Ongoing Challenges and Emerging Risks Despite 2024's improved financial performance, the industry continues to face significant headwinds which could impact future results: Legal System Abuse: Increased billboard attorney involvement in claims and larger jury awards drove auto liability losses and defense and cost containment expenses up by a range of $76.3 billion to $81.3 billion from 2014 to 2023, according to a 2024 Triple-I/Casualty Actuarial Society study. Regulatory Environment: State regulatory processes have become increasingly challenging, with approval timeframes for rate filings growing 40% longer from 2010 to 2023. Additionally, the percentage of filings receiving less rate impact than requested by carriers has increased by 10 percentage points, potentially limiting market availability and competitive pricing. Frequency vs. Severity Trends: While claim frequency remains below pre-pandemic levels, severity continues to rise year-over-year, with pure premium trends increasing cumulatively by 25.0 points from 2019 to 2024. About the Insurance Information Institute (Triple-I) Since 1960, the Insurance Information Institute (Triple-I) has been the trusted voice of risk and insurance, delivering unique, data-driven insights to educate, elevate and connect consumers, industry professionals, policymakers and the media. An affiliate of The Institutes, Triple-I represents a diverse membership accounting for nearly 50% of all U.S. property/casualty premiums written. Our members include mutual and stock companies, personal and commercial lines, primary insurers and reinsurers – serving regional, national and global markets. About The Institutes The Institutes® are a not-for-profit comprised of diverse affiliates that educate, elevate, and connect people in the essential disciplines of risk management and insurance. Through products and services offered by The Institutes and nearly 20 affiliated business units, people and organizations are empowered to help those in need with a focus on understanding, predicting, and preventing losses to create a more resilient world. The Institutes is a registered trademark of The Institutes. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store